Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. The vote was 9-3, sending to the FDA a recommendation that the Capricor treatment, called deramiocel, should not be approved. AdvertisementThe FDA is not required to adhere to the expert panel’s stance, but it typically does.